THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., Nov. 6, 2010
/PRNewswire/ — Amgen Inc. (Nasdaq:
AMGN), Pfizer Inc. (NYSE:
PFE) and world-class professional golfer Phil Mickelson, have
entered into a partnership to share Phil’s experience with his
diagnosis of psoriatic arthritis and treatment with Enbrel®
(etanercept), and to encourage patients with similar symptoms to
visit their doctor for proper assessment and care.
“This partnership with Amgen and Pfizer is important because
being a psoriatic arthritis patient has motivated me to share my
story,” said Phil Mickelson. “I hope to encourage other patients to
work with their doctors, learn about their condition and take
action so that they have an opportunity to get back to some of the
things that matter most to them.”
Psoriatic arthritis is a form of arthritis caused by an
overactive immune system that can affect not only the body’s joints
but also the skin. Approximately 600,000 Americans may have
psoriatic arthritis. The main joint symptoms of psoriatic arthritis
are pain, stiffness and swelling. Rheumatoid arthritis patients
experience similar symptoms, however there are important
differences between the two conditions, making it important to see
a doctor.
Amgen and Pfizer were inspired by Mickelson’s approach to
managing his condition and by his continued drive to maintain his
health. Those same qualities have kept him on top of the
competitive world of golf and this is why the companies are excited
to be partnering with him. Amgen and Pfizer believe his
perseverance in the face of adversity will encourage patients to
also work with their doctors to manage their condition and help
them get back on course.
Further details and timing of future partnership initiatives
will be announced in 2011.
About ENBRELE
‘/>”/>
